StockNews.AI
BMEA
StockNews.AI
9 hrs

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

1. Biomea Fusion to participate in Citi's Biotech Fireside Chat on October 23. 2. Discussing oral small molecule therapies for diabetes and obesity. 3. Targets a significant global health issue affecting nearly half of Americans. 4. Focuses on transformative treatments for diabetes and obesity-related conditions.

3m saved
Insight
Article

FAQ

Why Bullish?

Participation in key events boosts visibility and investor interest, similar to past biotech performances enhancing stock value.

How important is it?

The event can significantly increase stakeholder interest and credibility, positively affecting stock performance.

Why Short Term?

Immediate investor engagement is expected from the webcast, impacting stock prices shortly after the event.

Related Companies

VRTXMODVAMGN
October 21, 2025 19:05 ET  | Source: Biomea Fusion, Inc. SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. A live audio webcast of the discussion will be available here or by visiting the Investors & Media section of Biomea’s website at https://investors.biomeafusion.com/news-events/events. A replay of the webcast will be available following the live event. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure. Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. Contact:Meichiel Jennifer WeissSr. Director of Investor Relations and Corporate Development ir@biomeafusion.com

Related News